A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer

Trial Profile

A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs AMP 224 (Primary) ; Cyclophosphamide
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 03 Sep 2016 Planned End Date changed from 1 Nov 2016 to 1 Nov 2017.
    • 03 Sep 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top